New drug aims to tame dangerous side effects of powerful cancer treatment
Symptom relief
Recruiting now
This study is testing a new drug called CTO1681 to see if it can prevent or reduce severe side effects, specifically cytokine release syndrome (CRS), in adults with a type of lymphoma called DLBCL. Participants are people scheduled to receive a powerful cancer treatment called CA…
Phase: PHASE1, PHASE2 • Sponsor: CytoAgents, Inc. • Aim: Symptom relief
Last updated Apr 01, 2026 14:42 UTC